Abstract
Introduction
The E2F transcription factor is best known for its ability to regulate cell cycle progression by coordinating a large group of genes involved in G1-to-S phase transition. E2F regulated genes include cell cycle regulators, such as Cyclin E and Cdc25A, and genes that encode essential components of the DNA replication machinery [1] . [2] [3] [4] . E2F cell cycle activity is controlled through the temporally regulated physical association of pocket proteins. The hypophosphorylated retinoblastoma protein pRB represses E2F activity by shielding the E2F transactivation domain leading to restriction of cell cycle progression [5] . During the course of cell cycle progression through the restriction point, pRB becomes phosphorylated by the activity of cyclindependent kinases (Cdks) resulting in the release of E2F, thereby causing its activation (Fig. 1) . It is currently believed that most, and perhaps all, human cancers contain mutations that comprise pRB function E2F is a family composed of at least eight members that can be divided into distinct subgroups on the basis of their structural and functional similarities (reviewed in ref. [6] [7] , as well as unique roles during development, tissue homeostasis and apoptosis [8] . For [10] [11] [12] [13] , expression profiling studies [14] [15] [16] [17] and a recently performed proteomic analysis [18] showed that E2F proteins bind to and modulate expression of a large fraction of genes with diverse functions, suggesting a widespread role for E2F in the human genome. Currently, the best-characterized activity, especially at the hands of E2F1, in addition to its traditional role in cell cycle progression is its ability to induce apoptosis [19] [20] [21] [22] . In some set- [23] .
In agreement with the idea that E2F is an important regulator of cell proliferation, studies in several experimental systems have shown that the ectopic expression of E2F is sufficient to drive quiescent cells into S phase, while the inhibition of E2F-dependent transcription blocks cell proliferation

Fig. 1 During transition of cells from G1 to S phase, the activity of E2F is controlled by pRB, which binds E2F/DP, leading to transcriptional repression of E2F-responsive promoters in
Molecular mechanisms of E2F1-induced apoptosis
A large number of studies clearly support the role of E2F1 as a tumour suppressor rather than an oncogene [24] [25] [26] [24, 25] , and the level of apoptosis seen in RB -/-mice is suppressed by E2F1 deficiency [26] . Different mechanisms have been attributed to the ability of E2F1 to cause apoptosis, which can occur through both p53-dependent and independent pathways (Fig. 2) . In the p53-dependent pathway, p53 accumulates following E2F1 expression [27] through activation of the CDKN2A transcript p14ARF, which in turn interacts with Mdm2, thereby preventing Mdm2 from targeting p53 for ubiquitination and subsequent degradation [28] . Lately, additional ARFindependent pathways have been described [29] , and some reports even imply a negative feedback by ARF since over-expression of ARF inhibits E2F1-dependent apoptosis, and targets E2F1 for proteasomal degradation [30] . E2F1-induced apoptosis in the absence of ARF was shown to correlate with p53 phosphorylation at residues that are also phosphorylated in response to DNA damage [29, 31] . Moreover, induction of both apoptosis and p53 phosphorylation by E2F1 are abolished by the ATM and ATR protein kinase inhibitor caffeine [31] , supporting that E2F1 uses the ATM signalling pathway to induce p53 and Chk2 phosphorylation and thereby apoptosis [32, 33] . Correspondingly, it was reported that the E2F1 transcription factor elevates ATM promoter activity by direct binding, which is accompanied by enhanced p53 phosphorylation [34] . In addition, E2F1 interacts directly with p53 via the cyclin A-binding domain of E2F1, and this interaction enhances p53 apoptotic activity in response to DNA damage [35] .
E2F1-induced apoptosis occurs also independent of p53 in tissue culture and transgenic mice [36] [37] [38] , and pRB has been shown to protect p53-null cells from apoptosis in an E2F1-binding-dependent manner [39] . Apoptotic targets of E2F1 in the absence of p53 include the p53 homolog protein p73 [40, 41] and apoptosis protease-activating factor 1 (Apaf1) [42] both of which are transcriptionally regulated by E2F1. This initiates the assembly of Apaf1 with cytochrome c followed by procaspase-9 activation and successive initiation of proapoptotic effector caspases including .
Mapping studies revealed that the apoptotic ability of E2F1 requires the DNA-binding domain but not its transactivation function, since mutants of E2F1 that lack the transactivation domain are still able to induce cell death [36, 37, 43] . From these experiments, it was supposed that proapoptotic E2F1 target genes are activated by removal of E2F1/RB repression rather than direct transactivation. Moreover, Bell et al. [44] recently reported DNA-binding-independent cell death from a minimal proapoptotic region of E2F1 that is consequently unable to transactivate, repress or derepress E2F target genes. However, since this activity is also present in E2F2 and E2F3 proteins, it might therefore define a distinct mechanism of death by E2F proteins. [45] [46] [47] . In addition, DNA damage signals have been suggested to specifically activate E2F1-dependent transcription of proapoptotic genes [48] [49] [50] [51] [52] [53] [54] [55] [56] . In addition, endogenous E2F1 is up-regulated after DNA damage in a manner analogous to that of p53, suggesting its direct role in responsiveness to conventional genotoxic stress signals [57] . In response to DNA damage, the E2F1 protein is stabilized through distinct mechanisms, including direct phosphorylation by the ataxia-telangiectasia mutated (ATM) kinase, the ATM and RAD3-related (ATR) kinase and the Chk2 kinase [32, 48, 58] , and also by acetylation through p300/CREB-binding proteinassociated factor (P/CAF) [50] [14] [70] . [73] . These studies suggest that SIVA may function through multiple mechanisms possibly dependent on the cell type and apoptotic stimulus. In addition to the findings by Fortin et al. [72] indicating that the SIVA gene exhibits a striking induction during p53-mediated neuronal apoptosis, up-regulation of SIVA was also observed in p53-deficient hepatoma cells in response to cisplatinum-induced apoptosis [74] , suggesting that it is also regulated in a p53-independent manner, perhaps by E2F1.
Because normal cells proliferate without suffering E2F1-induced apoptosis, its proapoptotic potential is evidently held in check during development. How the switch between these activities is controlled is not well understood. Integration of external signals appears to play an important role in determining the sensitivity to E2F1-induced apoptosis. For example, cell survival signals via the PI3/AKT and the EGFR/Ras/Raf pathway have been shown to promote E2F1-driven cell proliferation by suppressing E2F1-induced apoptosis
Fig. 2 Mechanisms of E2F1-induced apoptosis. E2F1 promotes apoptosis via the tumour suppressor p53 and independent of p53. In the p53-dependent pathway, E2F1 activates ARF, which in turn stabilizes p53 by alleviating its proteosome degradation through Mdm2. ARF negatively regulates E2F1 in a feedback loop mechanism. In response to DNA damage E2F1 is stabilized through phosphorylation by ATM/ATR and Chk2 kinases (Chk2 also stabilizes p53 by phosphorylation). In addition, E2F1 interacts directly with p53 via the cyclin A binding domain, thereby inducing p53-mediated apoptosis. Alternatively, p53-independent apoptosis by E2F1 occurs via direct up-regulation of genes including p73 and Apaf-1. The assembly of Apaf1 with cytochrome c released from the mitochondria leads to formation of the apoptosome that catalyzes Caspase-9, and successive initiation of proapoptotic effector caspases including
. In the same study, KIAA0767, termed D(eath)-I(nducing)-P(rotein), was identified as a relevant apoptotic target of E2F1. The DIP protein is localized in the mitochondria and mediates E2F1-induced apoptosis independently of p53 in a partially caspase-independent manner [69]. In addition, transcriptional activation of the second mitochondrial activator of caspases or direct inhibitor-of-apoptosis-binding protein with low pI (Smac/DIABLO) was reported as a mechanism by which E2F1 promotes p53-independent apoptosis via the mitochondria
Caspases are essential components of the apoptotic machinery. These proteases are synthesized as inactive proenzymes and processed to an active state during apoptotic cell death. Initiator caspases (Caspase-2, -8 and -9) trigger a cascade that result in the activation of effector caspases (Caspase-3 and -7), which in turn produce the characteristic morphological changes associated with apoptosis. Enforced E2F1 expression has been shown to result in the accumulation of Caspase-2, -3, -7, -8 and -9 through a direct transcriptional mechanism [71]. E2F1 can facilitate caspase activation through p53-dependent signals, resulting in mitochondrial release of cytochrome c, while simultaneously increasing caspase expression through direct caspase promoter binding that is independent of p53. By up-regulation of caspases, particularly Caspase-8, E2F1 might sensitize cells to death-inducing ligands such as tumour necrosis factor (TNF). Another novel death effector protein of E2F1 is SIVA, which was identified to be directly up-regulated by E2F1 and p53 via their corresponding consensus sites in the SIVA promoter [72]. SIVA is a proapoptotic protein containing a death domain that is expressed on a broad scope of tissues, including cells of the immune system and the CNS as well as tumour cells. As a potential mechanism for apoptosis induction by SIVA, its interaction with members of the TNF-receptor family and antiapoptotic Bcl-2 family members has been considered
Some clarity has been shed on the requirement of the ASK1-p38 MAPK pathway for E2F1-induced apoptosis. The Ginsberg group [75] [76] . DNA microarray analysis revealed MAP3K5 up-regulation following E2F1 over-expression in p53-positive U-2OS osteosarcoma [77] and in p53-deficient melanoma cells [16] . MAPKs [80] and reporter gene assays [80, 83] . Since ASPP1 and ASPP2 are specific activators of the apoptotic function of all p53 family members, E2F1 may use this pathway to increase the apoptotic function of p63 and p73 independently of p53. This ambivalence seems to be a common concept for death proteins since it has also been observed for other apoptosis factors such as SIVA and MAP3K5. SIVA seems to link the E2F/ARF/p53-and the p53-independent apoptotic pathway [72] .
In a functional so-called technical knockout approach using the Saos-2 ER-E2F1 cell line, where E2F1 activity can be conditionally induced on 4-hydroxytamoxifen treatment, several other potential death targets of E2F1 were identified such as Galectin-1 (or LGALS1) [17] . E2F1-induced apoptosis was significantly abolished when Galectin-1 antisense cDNA was introduced into p53-negative cells. [84] . Consistently, E2F1 enhances Fas signalling in T cells [85] .
Galectin-1 has been shown to play a key role in tumour-immune escape by killing antitumour effector T cells. It sensitizes, for example, human-resting T cells to Fas (CD95)/caspase-8-mediated cell death
E2F1 was earlier shown to be essential for T-cell apoptosis by a process called T-cell receptor (TCR) activation-induced cell death (AICD). Lissy et al. [86] demonstrated that T cells were protected from TCR-mediated apoptosis by disruption of the E2F1 gene or p73. Together these findings support a function for E2F1 in balancing life and death of immune effector cells.
Inhibition of survival signalling pathways
Beside direct activation of various apoptosis-related genes described earlier, a second major mechanism by which E2F1 sensitizes cells to apoptosis is via inhibition of antiapoptotic signalling. One example is the inhibition of NF-B that functions in most cases as a survival signal. Activation of TNFR in response to TNF results in the stimulation of NF-B via TRAF2
, which contributes to the inhibition of cell death [87] . Importantly, E2F1 expression sensitizes cells to apoptosis by down-regulation of TRAF2 protein levels, thereby inhibiting antiapoptotic NF-B signalling [88] .
The general principle of blocking survival factors by E2F1 to induce apoptosis is supported by the data from two other studies [89, 90] [18] , which normally protects cells from death induced by disturbance of ER homeostasis [94, 95] . Moreover, expression of another ER chaperon, the 94 kD glucose-regulated protein (GRP94), shown to be significantly up-regulated in human esophageal cancers [96] , is also inhibited by E2F1 [18] . From these data it is evident that E2F1-mediated apoptosis involves both mitochondrial and ER-related death pathways. The whole spectrum of the proapoptotic activities of E2F1s is summarized in Figure 3 . 
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